EP
PVLA

Essential Partners’s Palvella Therapeutics PVLA Stock Holding History

Essential Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153 Buy
+1
New +$121 ﹤0.01% 2688

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Essential Partners's PVLA Position: Q2 2026 in Review

Essential Partners opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 1 share worth $153. The stake represents ﹤0.01% of the portfolio and ranks #2688 among its holdings.

197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Essential Partners held 1 share of Palvella Therapeutics worth $153 as of Q2 2026.
  • Palvella Therapeutics was a new Essential Partners position in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2688 holding.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.